Skip to main
MGNX
MGNX logo

MacroGenics (MGNX) Stock Forecast & Price Target

MacroGenics (MGNX) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 33%
Buy 46%
Hold 17%
Sell 4%
Strong Sell 0%

Bulls say

Macrogenics Inc has demonstrated promising preclinical data for its product candidates, indicating potentially greater potency and improved safety compared to existing therapies, which enhances the attractiveness of its pipeline. The company reported a 3Q24 net income of $0.90 per share, closely aligning with previous forecasts, suggesting stability in financial performance. The overall valuation remains fair, and upcoming datasets could further influence the outlook, potentially positively reinforcing investor confidence in Macrogenics's advancements in cancer therapeutics.

Bears say

Macrogenics Inc. faces a projected full-year net loss of $0.95 per share for 2024, indicating significant financial challenges ahead. The company's primary product, MARGENZA, may struggle to gain market traction due to fierce competition and various market factors, which poses a substantial risk to its financial sustainability. Additionally, potential clinical setbacks with key pipeline candidates, including vobramitamab duocarmazine and lorigerlimab, along with risks related to partnerships and long-term dilution, further contribute to a negative outlook for the company’s stock performance.

MacroGenics (MGNX) has been analyzed by 24 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 46% recommend Buy, 17% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MacroGenics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MacroGenics (MGNX) Forecast

Analysts have given MacroGenics (MGNX) a Buy based on their latest research and market trends.

According to 24 analysts, MacroGenics (MGNX) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MacroGenics (MGNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.